web analytics
Login
Subscribe
Breaking News         Nita Nee KC (2)     07/20/2014     Best In Show Judge: Mr. Stephen Hubbell     Best In Show: GCH StargazeR N Wingfield Wait Wait Don’t Tell [Dog]     Berrien KC     07/20/2014     Best In Show Judge: Mrs. Delores Burkholder     Best In Show: GCH Litilanns Show Time [Dog]     Hilton Head Island KC (2)     07/20/2014     Best In Show Judge: Mr. Norman Kenney     Best In Show: GCH Hill Countrys Tag IM It [Dog]     Paper Cities KC (2)     07/20/2014     Best In Show Judge: Dr. Anthony DiNardo     Best In Show: GCH Sonnus Filho (Sanchez) [Dog]     Galveston County KC     07/20/2014     Best In Show Judge: Mr. Arley Hussin     Best In Show: GCH Bugaboos Picture Perfect [Dog]     As the Wheels Turn – Murphy’s Law Sudden Acquired Retinal Degeneration Syndrome (SARDS) Monday Coffee Talk New York’s Hotel Pennsylvania Offers New, Exciting ‘Paw’menities for the 2015 Westminster Dog Show AVMA Applauds U.S. House For Passing a Bill That Allows Veterinarians to Provide Complete Care Beyond Their Clinics

We'll email you the stories that fanciers want to read from all around the web daily

We don't share your email address

FDA Approves First Oral Drug for Fleas and Ticks in Dogs with Three Month Duration

Approval marks second animal drug approval under collaborative initiative with Canada

June 3, 2014

The U.S. Food and Drug Administration’s Center for Veterinary Medicine (CVM) announced today the approval of BRAVECTO (fluralaner) Chewable Tablets for Dogs, the first oral flea and tick medication that lasts up to 12 weeks. The drug treats and prevents fleas for 12 weeks; treats and controls three types of ticks—the brown dog tick, American dog tick and deer tick—for 12 weeks; and treats and controls the lone star tick for 8 weeks.

The approval of BRAVECTO is in cooperation with Health Canada’s Veterinary Drugs Directorate (VDD), under the Regulatory Cooperation Council (RCC) joint initiative which aims to better align the approval process for these products. While maintaining safety standards, the RCC is intended to speed access to products, eliminate duplication, and reduce regulatory obstacles that can slow trade and investment opportunities as well as add costs to manufacturers and consumers. Under this initiative, FDA and VDD allow simultaneous submissions and collaborative reviews where possible, while maintaining each country’s right to decide whether or not products will be approved for its market.

The product is being marketed by Intervet Inc. and requires a valid prescription from a veterinarian for its use.

Written by